EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J Ullenhag

Cancer Immunology, Immunotherapy · 07.11.2024 · 74 (1)

DOI: 10.1007/s00262-024-03869-1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 07.11.2024. Verfasst von Cecilia Olsson Ladjevardi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerföreningen i Stockholm, Akademiska Sjukhuset, Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy with PD-1 or PD-L1 inhibitors has become an essential treatment strategy for a growing number of malignancies. These treatments have a risk for immune-related adverse events (IRAEs). Pooled analyses based on clinical trials show a favorable toxicity profile for treatment with PD-L1 compared to PD-1 inhibitors. This study aimed to investigate differences in IRAEs between patients with advanced solid malignances treated with PD-L1 and PD-1 inhibitors in a real-world setting. We conducted a retrospective cohort study at four Swedish Regions. Patients (n = 605) treated for advanced cancer with a PD-L1 or PD-1 inhibitor in monotherapy between June 2016 and August 2022 were included. Non-small cell lung cancer (NSCLC) was the most common malignant disease (n = 251; 41.5%), followed by malignant melanoma (n = 173; 28.6%), renal cell carcinoma (n = 71; 11.7%) and urothelial carcinoma (n = 35; 5.8%). Among patients receiving PD-L1 inhibitors, NSCLC (94.4%) was the predominant malignancy, whereas for those treated with PD-1 inhibitor, malignant melanoma constituted the most prevalent malignancy (34.5%). Discontinuation of treatment due to IRAEs overall and IRAEs grade ≥ 2 were significantly less common in patients treated with PD-L1 compared to PD-1 inhibitors [Odds Ratio (OR): 0.38 (95% Confidence Interval (CI) 0.16–0.88) and OR: 0.63 (95% CI 0.35–0.98) respectively]. Any grade IRAE, IRAE grade ≥ 3 and multiple IRAEs were numerically more frequent in patients treated with PD-1 inhibitors.In conclusion, our study of patients with advanced solid malignancies in a real-world setting supports the results from clinical trials demonstrating a favorable toxicity profile for PD-L1 inhibitors versus PD-1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorNeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenHumansRetrospective StudiesFemaleMaleAgedMiddle AgedAged, 80 and overAdultImmunotherapySwedenDrug-Related Side Effects and Adverse Reactions

Stichwörter der Autor:innen

Advanced cancerCohort studyImmune-related adverse eventsPD-1 inhibitorsPD-L1 inhibitors

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.
  • Thoracic Oncology Center, Theme Cancer, Karolinska University Hospital, 171 76, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
  • Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Department of Oncology, Mälarsjukhuset, 633 49, Eskilstuna, Sweden.

Förderung

  • Cancerföreningen i Stockholm
  • Akademiska Sjukhuset
  • Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
  • Örebro University

Zitieren

APA

Ladjevardi, C. O., Skribek, M., Koliadi, A., Rydén, V., El-Naggar, A. I., Digkas, E., Valachis, A., & Ullenhag, G. J. (2024). Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer. Cancer Immunology, Immunotherapy, 74(1). https://doi.org/10.1007/s00262-024-03869-1

Vancouver

Ladjevardi CO, Skribek M, Koliadi A, Rydén V, El-Naggar AI, Digkas E, et al. Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer. Cancer Immunology, Immunotherapy. 2024;74(1). doi:10.1007/s00262-024-03869-1

BibTeX
@article{Ladjevardi2024,
  author = {Ladjevardi, Cecilia Olsson and Skribek, Marcus and Koliadi, Anthoula and Rydén, Viktoria and El-Naggar, Ali Inan and Digkas, Evangelos and Valachis, Antonios and Ullenhag, Gustav J},
  title = {Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {74},
  number = {1},
  doi = {10.1007/s00262-024-03869-1}
}
Kostenlos starten →